Diagnosis and Treatment of Cognitive Impairments in Attention Deficit Syndrome in Adults
- 4 Downloads
Objectives. To clarify cognitive impairments in adults with attention deficit hyperactivity syndrome (ADHD) and to assess the efficacy of the formulation Memoplant in the treatment of this pathology. Materials and Methods. The results of clinical, psychological, and electroencephalographic studies of 40 patients aged 18–45 years with ADHD are presented. From recruitment into the study, all patients received Memoplant at a daily dose of 240 mg for eight weeks. Results and conclusions. Adult patients with ADHD had both subjective and objective impairments to memory and attention. EEG results suggested that patients showed dysfunction of the frontothalamic regulatory system and deficit of nonspecific activation by the reticular formation. Courses of Memoplant were followed by clinical improvements in 24 patients (60.0%). Repeat psychological and neurophysiological studies demonstrated decreases in attention deficit and improvements in memory measures.
Keywordsattention deficit hyperactivity disorder Memoplant
Unable to display preview. Download preview PDF.
- 5.I. T. Nureev, M. V. Zlokazova, and V. I. Tsirkin, “Experience in the use of the ASRS V1.1 questionnaire scales for the diagnosis of attention deficit hyperactivity disorder in adults,” Vestn. Pomorsk. Univ. Ser. Giziol. Psychol.-Pedagog. Nauk., 4, 98–102 (2007).Google Scholar
- 7.E. Murray, R. Pearson, M. Fernandes, I. S. Santos, F. C. Barros, C. G. Victora, A. Stein, and A. Matijasevich, “Are fetal growth impairment and preterm birth causally related to child attention problems and ADHD? Evidence from a comparison between high-income and middle-income cohorts,” J. Epidemiol. Community Health, 70, No. 7, 704–709 (2016), doi: https://doi.org/10.1136/jech-2015-206222.CrossRefPubMedPubMedCentralGoogle Scholar
- 8.O. R. Nogovitsina and E. V. Levitina, “Effects of perinatal risk factors on the formation of attention deficit hyperactivity disorder in children,” Ross. Vestn. Perinatol. Pediatr., 1, 64–65 (2012).Google Scholar
- 11.K. Ding, J. Yang, G. P. Reynolds, B. Chen, J. Shao, R. Liu, Q. Qian, H. Liu, R. Yang, J. Wen, and C. Kang, “DAT1 methylation is associated with methylphenidate response on oppositional and hyperactive-impulsive symptoms in children and adolescents with ADHD,” World J. Biol. Psychiatry, 27, 1–9 (2016), doi: https://doi.org/10.1080/15622975.2016.1224928. CrossRefGoogle Scholar
- 15.R. C. Kessler, L. A. Adler, M. J. Gruber, C. A. Sarawate, T. Spencer, and D. L. Van Brunt, “Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) screener in a representative sample of health plan members,” Int. J. Met. Psych. Res., 16, No. 2, 52–65 (2007), doi: https://doi.org/10.1002/mpr.208.CrossRefGoogle Scholar
- 16.D. E. Broadbent, P. F. Cooper, P. FitzGerald, and K. R. Parkes, “The Cognitive Failures Questionnaire (CFQ) and its correlates,” Br. J. Clin. Psychol., 21, 1–16 (1982), doi: https://doi.org/10.1111/j.2044-8260.1982.tb01421.x. CrossRefPubMedGoogle Scholar
- 17.Y. Luo, “Contemporary neuroscience meets traditional medicine – towards understanding Ginkgo biloba neuroprotection,” Curr. Top. Nutraceut. Res., 1, 49–58 (2003).Google Scholar
- 20.S. Blase, A. Gilbert, A. Anastopoulos, et al., “Self-reported ADHD and adjustment in college: cross-sectional and longitudinal findings,” J. Atten. Disord., 3, No. 13, 297–309 (2009), doi: https://doi.org/10.1177/1087054709334446.
- 21.R. G. Voigt, S. K. Katusic, R. C. Colligan, J. M. Killian, A. L. Weaver, and W. J. Barbaresi, “Academic achievement in adults with a history of childhood attention-deficit/hyperactivity disorder: A population-based prospective study,” J. Dev. Behav. Pediatr., 23, 1 (2016), doi: https://doi.org/10.1097/dbp.0000000000000358. CrossRefGoogle Scholar
- 22.R. A. Barkley and M. Fischer, “Predicting impairment in major life activities and occupational functioning in hyperactive children as adults: self-reported executive function (EF) deficits versus EF tests,” Dev. Neuropsychol., 36, 137–161 (2011), doi: https://doi.org/10.1080/87565641.2010.549877.CrossRefPubMedGoogle Scholar
- 24.T. Yoshitake, S. Yoshitake, and J. Kehr, “The Ginkgo biloba extract EGb 761(R) and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex,” Br. J. Pharmacol., 159, No. 3, 659–668 (2010), doi: https://doi.org/10.1111/j.1476-5381.2009.00580.x.CrossRefPubMedPubMedCentralGoogle Scholar
- 25.A. N. Boiko, A. V. Lebedeva, I. A. Shchukin, et al., “Potential of medication-based correction of moderate cognitive disorder,” Zh. Nevrol. Psikhiat., 2, 28–32 (2013).Google Scholar
- 26.I. V. Litvinenko, K. M. Naumov, and M. M. Odinak, “Correction of cognitive and noncognitive symptoms of cerebrovascular disease,” Zh. Nevrol. Psikhiat., 4, 35–40 (2014).Google Scholar
- 27.L. S. Chutko, S. Yu. Surushkina, A. V. Rozhkova, I. S. Nikishena, and E. A. Yakovenko, “Asthenic symptoms complex in patients with emotional burnout syndrome,” Zh. Nevrol. Psikhiat., No. 11, 22–26 (2013).Google Scholar